Literature DB >> 8384253

Long-term effects of vincristine on the peripheral nervous system.

T J Postma1, B A Benard, P C Huijgens, G J Ossenkoppele, J J Heimans.   

Abstract

Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system. The patients were interviewed with emphasis on neuropathic symptoms. Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment. Twenty-seven patients reported neuropathic symptoms. In 13 of these 27 patients symptoms were still present at the time of examination. In these patients sensory signs and symptoms predominated. In the other 14 patients symptoms had been present in the past. Symptoms persisted maximally 40 months since cessation of therapy. There was no age difference between patients with and without complaints at the time of examination. Normal reflexes were found in two third of patients. Neuropathic complaints were not very troublesome on the long term. It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384253     DOI: 10.1007/bf01050259

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  [Extensive motor neuropathy after a single dose of vincristine].

Authors:  P Benoit; A Destée; P Warot
Journal:  Therapie       Date:  1986 Nov-Dec       Impact factor: 2.070

Review 2.  Neurotoxicity of commonly used antineoplastic agents (second of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-18       Impact factor: 91.245

3.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases.

Authors:  J F Holland; C Scharlau; S Gailani; M J Krant; K B Olson; J Horton; B I Shnider; J J Lynch; A Owens; P P Carbone; J Colsky; D Grob; S P Miller; T C Hall
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

4.  Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man.

Authors:  P G Gottschalk; P J Dyck; J M Kiely
Journal:  Neurology       Date:  1968-09       Impact factor: 9.910

5.  Vincristine neuropathy: an electrophysiological and histological study.

Authors:  J G McLeod; R Penny
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

6.  Vincristine-induced neuropathy. A clinical study of fifty leukemic patients.

Authors:  S G Sandler; W Tobin; E S Henderson
Journal:  Neurology       Date:  1969-04       Impact factor: 9.910

7.  Studies on the pathogenesis of vincristine-induced neuropathy.

Authors:  Z Sahenk; S T Brady; J R Mendell
Journal:  Muscle Nerve       Date:  1987-01       Impact factor: 3.217

8.  Optic atrophy induced by vincristine.

Authors:  S B Shurin; H L Rekate; W Annable
Journal:  Pediatrics       Date:  1982-08       Impact factor: 7.124

9.  Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy.

Authors:  H E Hirvonen; T T Salmi; E Heinonen; K J Antila; I A Välimäki
Journal:  Cancer       Date:  1989-08-15       Impact factor: 6.860

10.  Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.

Authors:  D V Jackson; V S Sethi; C L Spurr; J M McWhorter
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

View more
  37 in total

1.  Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.

Authors:  Lyn M Huff; Dan L Sackett; Marianne S Poruchynsky; Tito Fojo
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

2.  Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.

Authors:  Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

3.  Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.

Authors:  Tejaswi Kandula; Michelle Anne Farrar; Richard J Cohn; David Mizrahi; Kate Carey; Karen Johnston; Matthew C Kiernan; Arun V Krishnan; Susanna B Park
Journal:  JAMA Neurol       Date:  2018-08-01       Impact factor: 18.302

4.  Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.

Authors:  Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger
Journal:  J Peripher Nerv Syst       Date:  2015-03       Impact factor: 3.494

5.  Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Haijun Zhang; Larry C Driver; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  J Pain       Date:  2011-06-24       Impact factor: 5.820

Review 6.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

7.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

8.  Anti-allodynic effect of theoesberiven F in a vincristine-induced neuropathy model.

Authors:  Seunguk Bang; Yee Suk Kim; Sang Rok Jeong
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

9.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

Review 10.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.